403 related articles for article (PubMed ID: 15504835)
1. Novel chemical class of pUL97 protein kinase-specific inhibitors with strong anticytomegaloviral activity.
Herget T; Freitag M; Morbitzer M; Kupfer R; Stamminger T; Marschall M
Antimicrob Agents Chemother; 2004 Nov; 48(11):4154-62. PubMed ID: 15504835
[TBL] [Abstract][Full Text] [Related]
2. The chemical class of quinazoline compounds provides a core structure for the design of anticytomegaloviral kinase inhibitors.
Hutterer C; Hamilton S; Steingruber M; Zeitträger I; Bahsi H; Thuma N; Naing Z; Örfi Z; Örfi L; Socher E; Sticht H; Rawlinson W; Chou S; Haupt VJ; Marschall M
Antiviral Res; 2016 Oct; 134():130-143. PubMed ID: 27515131
[TBL] [Abstract][Full Text] [Related]
3. Direct targeting of human cytomegalovirus protein kinase pUL97 by kinase inhibitors is a novel principle for antiviral therapy.
Marschall M; Stein-Gerlach M; Freitag M; Kupfer R; van den Bogaard M; Stamminger T
J Gen Virol; 2002 May; 83(Pt 5):1013-1023. PubMed ID: 11961255
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors of human cytomegalovirus replication drastically reduce the activity of the viral protein kinase pUL97.
Marschall M; Stein-Gerlach M; Freitag M; Kupfer R; van den Bogaard M; Stamminger T
J Gen Virol; 2001 Jun; 82(Pt 6):1439-1450. PubMed ID: 11369889
[TBL] [Abstract][Full Text] [Related]
5. Indolocarbazoles exhibit strong antiviral activity against human cytomegalovirus and are potent inhibitors of the pUL97 protein kinase.
Zimmermann A; Wilts H; Lenhardt M; Hahn M; Mertens T
Antiviral Res; 2000 Oct; 48(1):49-60. PubMed ID: 11080540
[TBL] [Abstract][Full Text] [Related]
6. Identification of inhibitors for a virally encoded protein kinase by 2 different screening systems: in vitro kinase assay and in-cell activity assay.
Mett H; Hölscher K; Degen H; Esdar C; De Neumann BF; Flicke B; Freudenreich T; Holzer G; Schinzel S; Stamminger T; Stein-Gerlach M; Marschall M; Herget T
J Biomol Screen; 2005 Feb; 10(1):36-45. PubMed ID: 15695342
[TBL] [Abstract][Full Text] [Related]
7. New reporter cell line to evaluate the sequential emergence of multiple human cytomegalovirus mutations during in vitro drug exposure.
Gilbert C; Boivin G
Antimicrob Agents Chemother; 2005 Dec; 49(12):4860-6. PubMed ID: 16304146
[TBL] [Abstract][Full Text] [Related]
8. A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture.
Cihlar T; Fuller MD; Mulato AS; Cherrington JM
Virology; 1998 Sep; 248(2):382-93. PubMed ID: 9721246
[TBL] [Abstract][Full Text] [Related]
9. The UL97 protein kinase of human cytomegalovirus and homologues in other herpesviruses: impact on virus and host.
Michel D; Mertens T
Biochim Biophys Acta; 2004 Mar; 1697(1-2):169-80. PubMed ID: 15023359
[TBL] [Abstract][Full Text] [Related]
10. Regulatory roles of protein kinases in cytomegalovirus replication.
Marschall M; Feichtinger S; Milbradt J
Adv Virus Res; 2011; 80():69-101. PubMed ID: 21762822
[TBL] [Abstract][Full Text] [Related]
11. New inhibitors of cytomegalovirus replication: in vitro evaluation, mechanism of action, and in vivo activity.
Neyts J; De Clercq E
Verh K Acad Geneeskd Belg; 1994; 56(6):561-92. PubMed ID: 7892749
[TBL] [Abstract][Full Text] [Related]
12. The human cytomegalovirus UL97 protein is phosphorylated and a component of virions.
van Zeijl M; Fairhurst J; Baum EZ; Sun L; Jones TR
Virology; 1997 Apr; 231(1):72-80. PubMed ID: 9143304
[TBL] [Abstract][Full Text] [Related]
13. Antiviral activity of artesunate towards wild-type, recombinant, and ganciclovir-resistant human cytomegaloviruses.
Efferth T; Marschall M; Wang X; Huong SM; Hauber I; Olbrich A; Kronschnabl M; Stamminger T; Huang ES
J Mol Med (Berl); 2002 Apr; 80(4):233-42. PubMed ID: 11976732
[TBL] [Abstract][Full Text] [Related]
14. Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet.
Drew WL; Miner RC; Marousek GI; Chou S
J Clin Virol; 2006 Oct; 37(2):124-7. PubMed ID: 16962820
[TBL] [Abstract][Full Text] [Related]
15. Comparison between human cytomegalovirus pUL97 and murine cytomegalovirus (MCMV) pM97 expressed by MCMV and vaccinia virus: pM97 does not confer ganciclovir sensitivity.
Wagner M; Michel D; Schaarschmidt P; Vaida B; Jonjic S; Messerle M; Mertens T; Koszinowski U
J Virol; 2000 Nov; 74(22):10729-36. PubMed ID: 11044117
[TBL] [Abstract][Full Text] [Related]
16. Contrasting effects on ganciclovir susceptibility and replicative capacity of two mutations at codon 466 of the human cytomegalovirus UL97 gene.
Martin M; Goyette N; Boivin G
J Clin Virol; 2010 Dec; 49(4):296-8. PubMed ID: 20843736
[TBL] [Abstract][Full Text] [Related]
17. Differential properties of cytomegalovirus pUL97 kinase isoforms affect viral replication and maribavir susceptibility.
Webel R; Hakki M; Prichard MN; Rawlinson WD; Marschall M; Chou S
J Virol; 2014 May; 88(9):4776-85. PubMed ID: 24522923
[TBL] [Abstract][Full Text] [Related]
18. Protein kinase inhibitors of the quinazoline class exert anti-cytomegaloviral activity in vitro and in vivo.
Schleiss M; Eickhoff J; Auerochs S; Leis M; Abele S; Rechter S; Choi Y; Anderson J; Scott G; Rawlinson W; Michel D; Ensminger S; Klebl B; Stamminger T; Marschall M
Antiviral Res; 2008 Jul; 79(1):49-61. PubMed ID: 18329738
[TBL] [Abstract][Full Text] [Related]
19. Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance.
Piret J; Boivin G
Antiviral Res; 2019 Mar; 163():91-105. PubMed ID: 30690043
[TBL] [Abstract][Full Text] [Related]
20. Human cytomegalovirus double resistance in a donor-positive/recipient-negative lung transplant patient with an impaired CD4-mediated specific immune response.
Baldanti F; Lilleri D; Campanini G; Comolli G; Ridolfo AL; Rusconi S; Gerna G
J Antimicrob Chemother; 2004 Mar; 53(3):536-9. PubMed ID: 14739146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
